{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:07:57Z","timestamp":1767848877049,"version":"3.49.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Simple Endoscopic Score for Crohn\u2019s disease (SES-CD) and Modified Multiplier of the SES-CD (MM-SES-CD) are endoscopic scoring systems used to assess disease severity and response to therapy in CD. This study evaluates their utility at baseline in predicting endoscopic remission (ER) of the ileum and colon at week 52.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post-hoc analysis of 4 clinical trials (CT-P13, UNITI, EXTEND, and SEAVUE) compared baseline scores and ER outcomes at week 52 using the SES-CD and MM-SES-CD. The area under the receiver operating characteristic curve (AUC) for each scoring system\u2019s ability to predict week 52 ER defined by various thresholds was compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 667 patients were included in this analysis. At baseline, the median SES-CD score was 8.5 (IQR 5.0\u201315.7), and the median MM-SES-CD score was 34.8 (IQR 27.5\u201350.0). MM-SES-CD demonstrated consistently higher AUC values compared to SES-CD across most endpoints in ileal and colonic disease involvement. Among 519 patients with any disease in the ileum, baseline MM-SES-CD demonstrated significantly better predictive accuracy than SES-CD for week 52 SES-CD\u2005&amp;lt;\u20053 [AUC 0.75 (95% CI: 0.71\u20130.80) vs. 0.64 (95% CI: 0.59\u20130.70), P\u2005=\u2005.031]. Similar findings were observed for other definitions of ER. Among 552 participants with colonic disease involvement, baseline MM-SES-CD also demonstrated significantly greater accuracy for predicting week 52 SES-CD\u2005&amp;lt;\u20053 [AUC 0.78 (95% CI: 0.73\u20130.82) vs. 0.62 (95% CI: 0.57\u20130.66), P\u2005=\u2005.002], with similar findings across other definitions of ER assessed. Similar trends were observed across isolated ileal, ileocolonic, and isolated colonic disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The baseline MM-SES-CD demonstrated superior predictive ability for week 52 ER compared to SES-CD across the ileum and colon. These findings support its utility in clinical trials and in routine practice for predicting long-term treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf124","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T09:14:00Z","timestamp":1747818840000},"page":"3044-3050","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Predictive Utility of MM-SES-CD and SES-CD for Week 52 Endoscopic Remission in the Ileum and Colon in Crohn\u2019s Disease"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9472-201X","authenticated-orcid":false,"given":"Emily C L","family":"Wong","sequence":"first","affiliation":[{"name":"Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University , Hamilton, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9514-2321","authenticated-orcid":false,"given":"Parambir S","family":"Dulai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Northwestern University , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K","family":"Marshall","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University , Hamilton, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Western University , London, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-091X","authenticated-orcid":false,"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-8436","authenticated-orcid":false,"given":"Neeraj","family":"Narula","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, McMaster University , Hamilton, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"issue":"10080","key":"2025112116465537300_CIT0001","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"4","key":"2025112116465537300_CIT0002","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/s0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc."},{"issue":"6","key":"2025112116465537300_CIT0003","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/gutjnl-2020-323799","article-title":"Predicting endoscopic remission in Crohn\u2019s disease by the modified multiplier SES-CD (MM-SES-CD)","volume":"71","author":"Narula","year":"2021","journal-title":"Gut."},{"issue":"4","key":"2025112116465537300_CIT0004","doi-asserted-by":"publisher","first-page":"jjae171","DOI":"10.1093\/ecco-jcc\/jjae171","article-title":"Use of MM-SES-CD endoscopic improvement thresholds enhances effect size differentiation between Adalimumab vs. Placebo: a post-hoc analysis of the EXTEND Trial","volume":"19","author":"Wong","year":"2024","journal-title":"J Crohns Colitis."},{"issue":"5","key":"2025112116465537300_CIT0005","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology."},{"issue":"20","key":"2025112116465537300_CIT0006","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"issue":"10182","key":"2025112116465537300_CIT0007","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","article-title":"Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn\u2019s disease: an international, randomised, double-blind, phase 3 non-inferiority study","volume":"393","author":"Ye","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"10342","key":"2025112116465537300_CIT0008","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"8","key":"2025112116465537300_CIT0009","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.cgh.2024.02.009","article-title":"Defining endoscopic remission in Crohn\u2019s disease: MM-SES-CD and SES-CD thresholds associated with low risk of disease progression","volume":"22","author":"Narula","year":"2024","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"3","key":"2025112116465537300_CIT0010","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn\u2019s disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med."},{"issue":"10340","key":"2025112116465537300_CIT0011","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"d\u2019Haens","year":"2022","journal-title":"Lancet (London, England)"},{"issue":"25","key":"2025112116465537300_CIT0012","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1053\/j.gastro.2025.02.033","article-title":"Efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn\u2019s disease: results from the phase 3 GRAVITI Study","volume":"S0016-5085","author":"Hart","year":"2025","journal-title":"Gastroenterology."},{"issue":"4","key":"2025112116465537300_CIT0013","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/ecco-jcc\/jjw178","article-title":"Characterisation of mucosal healing with adalimumab treatment in patients with moderately to severely active Crohn\u2019s disease: results from the EXTEND Trial","volume":"11","author":"Reinisch","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"4","key":"2025112116465537300_CIT0014","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1053\/j.gastro.2019.06.038","article-title":"Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn\u2019s disease","volume":"157","author":"Danese","year":"2019","journal-title":"Gastroenterology."},{"issue":"8","key":"2025112116465537300_CIT0015","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.14309\/ajg.0000000000000617","article-title":"Ileal and rectal ulcer size affects the ability to achieve endoscopic remission: a post hoc analysis of the SONIC trial","volume":"115","author":"Narula","year":"2020","journal-title":"Am J Gastroenterol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf124\/63500614\/izaf124.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/11\/3044\/63500614\/izaf124.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/11\/3044\/63500614\/izaf124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T21:47:03Z","timestamp":1763761623000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/11\/3044\/8163882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":15,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,16]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf124","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,16]]}}}